EPI-321

Phase 2Biologic

EEpicrispr Biotechnologies, Inc.

EPI-321 is one of 4 biologic programs targeting Facioscapulohumeral Muscular Dystrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Facioscapulohumeral Muscular DystrophyActive, not recruiting

Facioscapulohumeral Muscular DystrophyPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Facioscapulohumeral Muscular Dystrophy

#DrugCompanyPhaseTrials

AOC 1020

AAvidity Biosciences, Inc.

Phase 3

1 2

Apitegromab

SScholar Rock, Inc.

Phase 2

1 3

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

1 4

EPI-321

EEpicrispr Biotechnologies, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

PreclinicalActive, not recruiting

Facioscapulohumeral Muscular Dystrophy

NCT06907875

Clinical

Trials by Indication[1]

Facioscapulohumeral Muscular Dystrophy1 trial

A Phase 1/2 Open-label Dose-escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of EPI-321, an AAVrh74-delivered Epigenetic Editing Therapy in Adult FSHD Patients

Active, not recruiting·EEpicrispr Biotechnologies, Inc.·Preclinical·NCT06907875·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EPI-321. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EPI-321 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EPI-321. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Epicrispr Biotechnologies, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: EEpicrispr Biotechnologies, Inc.

EPI-321

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Facioscapulohumeral Muscular Dystrophy1 trial

References

Drug Info

Quick Facts

Related News